Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
98.64
-3.88 (-3.78%)
Streaming Delayed Price
Updated: 12:12 PM EST, Dec 8, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corporation - Common Stock
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
24
25
Next >
Analyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm'
↗
October 17, 2022
Via
Benzinga
Incyte to Report Third Quarter Financial Results
October 11, 2022
From
Incyte
Via
Business Wire
2 Cathie Wood Stocks That Are Beating the Market This Year
↗
October 07, 2022
One is doing much better than the other year to date, but they both have solid prospects ahead.
Via
The Motley Fool
Incyte Names New Member to Its Board of Directors
October 04, 2022
From
Incyte
Via
Business Wire
Incyte Acquires Villaris Therapeutics, Deepening Portfolio For Immune-Mediated Dermatologic Diseases
↗
October 03, 2022
Via
Benzinga
MorphoSys' Monjuvi Shows Long-Term Durable Response In Blood Cancer Settings
↗
September 29, 2022
Via
Benzinga
Incyte Q2 Earnings Beat Estimates But Tightens FY22 Jakafi Sales Guidance
↗
August 02, 2022
Via
Benzinga
Recap: Incyte Q2 Earnings
↗
August 02, 2022
Incyte (NASDAQ:INCY) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody
October 03, 2022
From
Incyte
Via
Business Wire
Death Cross Looms Over Incyte Investors
↗
September 22, 2022
If history is any guide, there may be trouble ahead for shares of Incyte (NASDAQ:INCY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Via
Benzinga
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
↗
September 15, 2022
Via
Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
↗
August 26, 2022
Via
Benzinga
Expert Ratings for Incyte
↗
July 28, 2022
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Incyte Gets FDA Nod For Hematologic Malignancies Candidate
↗
August 26, 2022
The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ: INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with...
Via
Benzinga
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
August 26, 2022
From
Incyte
Via
Business Wire
Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
August 24, 2022
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
August 23, 2022
From
Incyte
Via
Business Wire
10 Most Oversold Stocks To Buy In August 2022
↗
August 10, 2022
Looking for some oversold stocks to buy? Here's the 10 most oversold on the S&P 500 for August 2022.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
↗
August 03, 2022
Via
Benzinga
Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled
↗
August 02, 2022
Jakafi sales beat and the company raised its guidance. But another drug fell short.
Via
Investor's Business Daily
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
↗
August 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
August 02, 2022
From
Incyte
Via
Business Wire
Biotech Investors: August's Key PDUFA Catalysts You Must Know
↗
July 31, 2022
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...
Via
Benzinga
New Indication Approval For Incyte "To Usher New Growth Avenue"
↗
July 21, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
↗
July 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
↗
July 28, 2022
Via
Benzinga
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
July 18, 2022
From
Incyte
Via
Business Wire
The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine
↗
July 18, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Incyte to Report Second Quarter Financial Results
July 12, 2022
From
Incyte
Via
Business Wire
Twitter And 3 Other Stocks Insiders Are Selling
↗
July 12, 2022
US crude oil futures traded sharply lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
24
25
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
